PA
SLN

Parallel Advisors’s Silence Therapeutics SLN Stock Holding History

Parallel Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.85K Hold
1,300
– – ﹤0.01% 2918
2025
Q4 		$7.9K Hold
1,300
– – ﹤0.01% 2703
2025
Q3 		$6.75K Hold
1,300
– – ﹤0.01% 2663
2025
Q2 		$7.54K Hold
1,300
– – ﹤0.01% 2594
2025
Q1 		$3.67K Buy
+1,300
New +$6.35K ﹤0.01% 2786

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Parallel Advisors's SLN Position: Q1 2026 in Review

Parallel Advisors held its Silence Therapeutics (SLN) position steady in Q1 2026 at 1,300 shares worth $6.85K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Parallel Advisors first reported a position in SLN in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.9K in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Parallel Advisors held 1,300 shares of Silence Therapeutics worth $6.85K as of Q1 2026.
  • Parallel Advisors left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2918 holding.
  • Parallel Advisors first reported a position in Silence Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Parallel Advisors's Silence Therapeutics position peaked at $7.9K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.